Drug Profile
Avutometinib - Verastem Oncology
Alternative Names: CH 5127566; CH-5126766; CKI-27; R-7304; RG 7304; RO-5126766; VS-6766Latest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical; Thomas Jefferson University
- Developer Amgen; Chugai Pharmaceutical; Eli Lilly and Company; European Network of Gynaecological Oncological Trial Groups; Gynecologic Oncology Group; Memorial Sloan-Kettering Cancer Center; Roche; Royal Marsden NHS Foundation Trust; Verastem Oncology
- Class Antineoplastics; Hydrazines; Ketones; Pyridazines; Small molecules
- Mechanism of Action Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ovarian cancer
- Phase II Gynaecological cancer; Non-small cell lung cancer; Thyroid cancer; Uveal melanoma
- Phase I/II Colorectal cancer; HER2 negative breast cancer; Malignant melanoma; Pancreatic cancer; Solid tumours
- No development reported Multiple myeloma
Most Recent Events
- 16 Apr 2024 M.D. Anderson Cancer Center plans a phase-II trial for Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater; Inoperable/Unresectable) in the US in October 2024 (NCT06369259)
- 14 Mar 2024 Verastem plans to initiate discussions with European and Japanese authorities for approval of avutometinib and defactinib combination in Ovarian cancer
- 07 Mar 2024 Verastem Oncology announces intention to launch avutometinib in Ovarian Cancer in 2025